Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells originally described to hamper immune responses in chronic infections. Meanwhile, they are known to be a major obstacle in cancer immunotherapy. On the other hand, MDSC can interfere with allogeneic transplant rejection and may dampen autoreactive T cell activity. Whether MDSC-Exosomes (Exo) can cope with the dangerous and potentially therapeutic activities of MDSC is not yet fully explored. After introducing MDSC and Exo, it will be discussed, whether a blockade of MDSC-Exo could foster the efficacy of immunotherapy in cancer and mitigate tumor progression supporting activities of MDSC. It also will be outlined, whether application of native or tailored MDSC-Exo might prohibit autoimmune disease progression. These considerations are based on the steadily increasing knowledge on Exo composition, their capacity to distribute throughout the organism combined with selectivity of targeting, and the ease to tailor Exo and includes open questions that answers will facilitate optimizing protocols for a MDSC-Exo blockade in cancer as well as for strengthening their therapeutic efficacy in autoimmune disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Routes and mechanisms of extracellular vesicle uptake
Mulcahy, L. A., Pink, R. C., & Carter, D. R. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24641 · Cited by 2,832
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730 · cited 1×
“Exo uptake also depending on target cell ligands, may require different target structures then binding and can have distinct consequences for the target cell (125, 126).”
BackgroundMechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes.
Montecalvo, A., Larregina, A. T., Shufesky, W. J., Beer Stolz, D., Sullivan, M. L. G., Karlsson, J. M., Baty, C. J., Gibson, G. A., Erdos, G., Wang, Z., et al. (2012) · Blood · doi:10.1182/blood-2011-02-338004 · Cited by 1,429 · cited 1×
“There are two modalities for Exo uptake, fusion with the cell membrane (135, 136) and, dominating, endocytosis, an active process that requires modulation of the actin cytoskeleton (135, 137–139).”
MethodHistory of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J.-P., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304266110 · Cited by 903
Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte–Neuron Communication
Frühbeis, C., Fröhlich, D., Kuo, W. P., Amphornrat, J., Thilemann, S., Saab, A. S., Kirchhoff, F., Möbius, W., Goebbels, S., Nave, K.-A., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001604 · Cited by 902
Extracellular vesicles round off communication in the nervous system
Budnik, V., Ruiz-Cañada, C., & Wendler, F. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.29 · Cited by 712
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease
Harris, H. E., Andersson, U., & Pisetsky, D. S. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.222 · Cited by 689 · cited 3×
“HMBG1, a chaperone for many inflammatory molecules in MDSC, promotes the development of MDSC from BM progenitors, increases IL10 production by MDSC and contributes to downregulation of the T cell homing receptor CD62L (203, 204).”
BackgroundKim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.09.011 · Cited by 663 · cited 2×
“org February 2018 | Volume 9 | Article 137 Last not least, Exo or Exo surrogates can be loaded with drugs, toxins, non-coding RNA to be delivered toward MDSC or MDSCExo to directly prohibit their immunosuppressive, angiogenesis and cancer-spread promoting activities (175, 178, 228, 229).”
BackgroundSaari, H., Lázaro-Ibáñez, E., Viitala, T., Vuorimaa-Laukkanen, E., Siljander, P., & Yliperttula, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.031 · Cited by 613
Yim, N., Ryu, S.-W., Choi, K., Lee, K. R., Lee, S., Choi, H., Kim, J., Shaker, M. R., Sun, W., Park, J.-H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12277 · Cited by 578
Phagocytosis: Receptors, signal integration, and the cytoskeleton
Freeman, S. A., & Grinstein, S. (2014) · Immunological Reviews · doi:10.1111/imr.12212 · Cited by 548
Exosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546
Trans-Synaptic Transmission of Vesicular Wnt Signals through Evi/Wntless
Korkut, C., Ataman, B., Ramachandran, P., Ashley, J., Barria, R., Gherbesi, N., & Budnik, V. (2009) · Cell · doi:10.1016/j.cell.2009.07.051 · Cited by 443
Kogure, T., Yan, I. K., Lin, W.-L., & Patel, T. (2013) · Genes & Cancer · doi:10.1177/1947601913499020 · Cited by 303
Iraci, N., Leonardi, T., Gessler, F., Vega, B., & Pluchino, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020171 · Cited by 301
Regulation of Postsynaptic Retrograde Signaling by Presynaptic Exosome Release
Korkut, C., Li, Y., Koles, K., Brewer, C., Ashley, J., Yoshihara, M., & Budnik, V. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.013 · Cited by 250
Nishida-Aoki, N., Tominaga, N., Takeshita, F., Sonoda, H., Yoshioka, Y., & Ochiya, T. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.009 · Cited by 208 · cited 1×
“According to the enrichment of tetraspanins, anti-CD9 was shown to prohibit breast cancer cell metastasis (221).”
BackgroundCantoni, C., Cignarella, F., Ghezzi, L., Mikesell, B., Bollman, B., Berrien-Elliott, M. M., Ireland, A. R., Fehniger, T. A., Wu, G. F., & Piccio, L. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1621-6 · Cited by 96
Cited by
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
The role of exosomal PD-L1 in tumor progression and immunotherapy
Xie, F., Xu, M., Lu, J., Mao, L., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1074-3 · Cited by 348
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 281
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment
Tian, X., Shen, H., Li, Z., Wang, T., & Wang, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0772-z · Cited by 264
Wang, Y., Yin, K., Tian, J., Xia, X., Ma, J., Tang, X., Xu, H., & Wang, S. (2019) · Advanced Science · doi:10.1002/advs.201901278 · Cited by 211
Metadata
- Authors
- Zöller, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-02-02
- Volume
- 9
- Pages
- 137-137
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2791267664
- Cited by
- 47
- References
- 22
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.